OnLume Earns $300K SBIR Grant
OnLume, a medical device company developing surgical lighting technology, is the recipient of a Phase I SBIR grant through the National Cancer Institute SBIR worth $300,000. “At OnLume, we believe…
OnLume, a medical device company developing surgical lighting technology, is the recipient of a Phase I SBIR grant through the National Cancer Institute SBIR worth $300,000. “At OnLume, we believe…
Cellectar Biosciences today announced the effective price of $1.50 per share of common stock of an underwritten public offering to raise approximately $8 million. According to a release, Cellectar will use…
Madison Vaccines Incorporated (MVI) announced today it will present data at the Society for Immunotherapy of Cancer’s Annual Meeting on Nov. 11 in National Harbor, Md., that has “promise” to stimulate an immune…
Propeller Health received clearance from the U.S. Food and Drug Administration on its Propeller platform for use with GlaxoSmithKline’s Ellipta inhaler, the company announced today. “Today, we are pleased to announce…
JangoBio recently announced its founding as a biotech company focused on restoring hormones to their optimal youthful levels. The pre-clinical stage company was formed in 2015 and is developing new therapies to sustainably…
Propeller Health announced today that it completed a $21.5 million Series C financing round. According to a release, the funds will be used to expand the company’s digitally guided therapy…
Exact Sciences’ Cologuard continues to expand its coverage as it is now included under TRICARE’s preventive services policies, the company announced today. TRICARE provides benefits to 9.4 million active-duty, reserve and…
Exact Sciences’ Cologuard is now included in the 2017 Healthcare Effectiveness Data and Information Set (HEDIS) quality measures for colorectal cancer screening, the organization announced recently. “Cologuard’s inclusion in the…
SHINE Medical Technologies announced this week that it is moving its headquarters from Monona, Wis., to Janesville, Wis., later this year. According to a release, all of SHINE’s employees will…
Cellectar Biosciences’ CLR 131, its lead therapeutic compound, will be used in a University of Wisconsin study of neck and head cancers, the organization announced today. According to a release,…